LIfT BioSciences raises £10m in first close of Series A to advance first-in-class allogeneic innate cell therapy
Tony De Fougerolles shares his experiences in developing industry-disrupting technologies, meeting LIfT’s CEO Alex Blyth, and his reasons for becoming Chairman of LIfT’s Board of Directors